TET2 rabbit pAb

  • Catalog No.:YT8098
  • Applications:IHC;WB
  • Reactivity:Human;Mouse
    • Target:
    • TET2
    • Gene Name:
    • TET2 KIAA1546 Nbla00191
    • Protein Name:
    • Methylcytosine dioxygenase TET2 (EC 1.14.11.n2)
    • Human Swiss Prot No:
    • Q6N021
    • Mouse Swiss Prot No:
    • Q4JK59
    • Immunogen:
    • Synthesized peptide derived from human C-ternal TET2
    • Specificity:
    • This antibody detects endogenous levels of TET2 at Human, Mouse
    • Formulation:
    • Liquid in PBS containing 50% glycerol, and 0.02% sodium azide.
    • Source:
    • Polyclonal, Rabbit,IgG
    • Dilution:
    • WB 1:500-2000 IHC 1:50-200
    • Purification:
    • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
    • Concentration:
    • 1 mg/ml
    • Storage Stability:
    • -15°C to -25°C/1 year(Do not lower than -25°C)
    • Other Name:
    • Methylcytosine dioxygenase TET2 (EC 1.14.11.n2)
    • Molecular Weight(Da):
    • 220kD
    • Function:
    • Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Has a preference for 5-hydroxymethylcytosine in CpG motifs. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation. Methylation at the C5 position of cytosine bases is an epigenetic modification of the mammalian genome which plays an important role in transcriptional regulation. In addition to its role in DNA demethylation, also involved in the recruitment of the O-GlcNAc transferase OGT to CpG-rich transcription start sites of active genes, thereby promoting histone H2B GlcNAcylation by OGT.
    • Expression:
    • Broadly expressed. Highly expressed in hematopoietic cells; highest expression observed in granulocytes. Expression is reduced in granulocytes from peripheral blood of patients affected by myelodysplastic syndromes.